Immunotherapy for Melanoma: The Significance of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma

Research output: Contribution to journalReview articlepeer-review

11 Citations (Scopus)

Abstract

Therapeutic options for treating advanced melanoma have progressed rapidly in recent decades. Until 6 years ago, the regimen for treating advanced melanoma consisted mainly of cytotoxic agents such as dacarbazine and type I interferons. Since 2014, anti-programmed cell death 1 (PD1) antibodies have been recognized as anchor drugs for treating advanced melanoma, with or without additional combination drugs such as ipilimumab, but the efficacies of these immunotherapies are not fully satisfactory. In this review, we describe the development of the currently available anti-PD1 Abs-based immunotherapies for advanced melanoma, focusing on their efficacy and immune-related adverse events (AEs), as well as clinical trials still ongoing for the future treatment of advanced melanoma.

Original languageEnglish
Article number15720
JournalInternational Journal of Molecular Sciences
Volume23
Issue number24
DOIs
Publication statusPublished - 2022 Dec

Keywords

  • advanced melanoma
  • anti-CTLA4 Abs
  • anti-PD1 Abs
  • efficacy
  • immune checkpoint inhibitors
  • irAEs

Fingerprint

Dive into the research topics of 'Immunotherapy for Melanoma: The Significance of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma'. Together they form a unique fingerprint.

Cite this